CYTOMX THERAPEUTICS ANNOUNCES APPOINTMENT OF CARLOS CAMPOY AS CHIEF FINANCIAL OFFICER
23 Marzo 2020 - 2:02PM
CytomX Therapeutics, Inc. (NASDAQ: CTMX), a clinical-stage
oncology-focused biopharmaceutical company pioneering a novel class
of investigational antibody therapeutics based on its Probody®
therapeutic technology platform, today announced the appointment of
Carlos Campoy as senior vice president and chief financial officer.
“Carlos brings to CytomX a broad range of global financial
expertise within the healthcare industry that will be of great
value to us as we continue to build our company,” said Sean
McCarthy, D.Phil., president, chief executive officer and chairman
of CytomX Therapeutics. “In addition, Carlos’ technical, strategic
and leadership experience further strengthens the CytomX team and
builds upon several key recent appointments. The team and I
look forward to working closely with Carlos in advancing our vision
and mission of developing innovative new treatment options for
patients with cancer.”
Mr. Campoy brings over 30 years of financial and leadership
experience, the majority from publicly held companies within the
healthcare and biopharmaceutical sectors. Most recently, Mr. Campoy
held the position of chief financial officer at Alder
BioPharmaceuticals, which was acquired in October 2019 by Lundbeck
A/S, where he led the finance organization and readied the company
for commercial launch of its lead program, eptinezumab, a recently
approved treatment for the prevention of migraine. Prior to
Alder, Mr. Campoy held the role of vice president of finance,
international at Allergan plc. Prior to joining Allergan, over the
course of an 18-year tenure at Eli Lilly and Company, Mr. Campoy
held senior financial leadership positions including most recently
as chief financial officer of Eli Lilly Japan K.K. Mr. Campoy
received his M.B.A. in Finance and Decision Information Systems
from Indiana University and his B.S. in Management from Faculdade
C.C. Administracao de Tupa, in São Paulo, Brazil. Mr. Campoy holds
a Certified Management Accountant (CMA) designation.
"I am excited to be joining CytomX as the company’s Probody
portfolio continues to mature and advance to address important
areas of unmet medical need in cancer,” said Mr. Campoy. “I look
forward to making significant contributions to the company’s
strategic, financial and operational initiatives as we continue to
build a top-tier organization.”
About CytomX
Therapeutics CytomX is a clinical-stage,
oncology-focused biopharmaceutical company with a vision of
transforming lives with safer, more effective therapies. We are
developing a novel class of investigational antibody therapeutics,
based on our Probody® technology platform, for the treatment of
cancer. As leaders in the field, our innovative technology is
designed to turn previously undruggable targets into druggable
targets and to enable more effective combination therapies. CytomX
and its partners, comprised of leading biotechnology and
pharmaceutical companies, have developed a robust pipeline of
potential best-in-class immunotherapeutic candidates against
clinically validated targets and potential first-in-class
therapeutic candidates against novel, difficult to drug targets.
Five novel drug-candidates utilizing our Probody technology are in
the clinic, with three in Phase 2 studies and two in Phase 1
studies. These clinical programs include cancer immunotherapeutic
candidates against validated targets such as a PD-L1-targeting
Probody therapeutic wholly owned by CytomX (CX-072) and two
CTLA-4-targeting Probody therapeutic candidates partnered with
Bristol-Myers Squibb (BMS-986249 and BMS-986288). The CytomX
clinical stage pipeline also includes first-in-class Probody drug
conjugate product candidates against previously undruggable
targets, including a CD166-targeting Probody drug conjugate wholly
owned by CytomX (CX-2009) and a CD71-targeting Probody drug
conjugate partnered with AbbVie (CX-2029). CD166 and CD71 are among
cancer targets that are considered to be inaccessible to
conventional antibody drug conjugates due to their presence on many
healthy tissues. In addition to its wholly owned programs, CytomX
has strategic collaborations with AbbVie, Amgen and Bristol-Myers
Squibb. For additional information about CytomX Therapeutics,
visit www.cytomx.com and follow us
on LinkedIn and Twitter. CytomX Therapeutics
Forward-Looking Statements This press release includes
forward-looking statements. Such forward-looking statements involve
known and unknown risks, uncertainties and other important factors
that are difficult to predict, may be beyond our control, and may
cause the actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied in such statements. Accordingly,
you should not rely on any of these forward-looking statements,
including those relating to the potential benefits, safety and
efficacy of CytomX’s or any of its collaborative partners’ product
candidates, administered separately or in combination and the
potential benefits or applications of CytomX’s Probody platform
technology. Risks and uncertainties that contribute to the
uncertain nature of the forward-looking statements include: the
unproven nature of CytomX’s novel Probody Platform technology; five
product candidates under CytomX’s Probody platform are in the
initial stages of clinical development and its other product
candidates are currently in preclinical development, and the
process by which preclinical and clinical development could
potentially lead to an approved product is long and subject to
significant risks and uncertainties. Additional applicable
risks and uncertainties include those relating to our preclinical
research and development, clinical development, and other risks
identified under the heading "Risk Factors" included in CytomX’s
Annual Report on Form 10-K filed with the SEC on February 27, 2020.
The forward-looking statements contained in this press release are
based on information currently available to CytomX and speak only
as of the date on which they are made. CytomX does not undertake
and specifically disclaims any obligation to update any
forward-looking statements, whether as a result of any new
information, future events, changed circumstances or otherwise.
Probody is a U.S. registered trademark of CytomX
Therapeutics, Inc.
Investor and Media Contact:
Christopher Keenan VP, Investor Relations and Corporate
Communications ckeenan@cytomx.com 650-383-0823
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/c5e5a03c-5d49-43ac-87c7-10969d380c2c
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024